These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33830342)

  • 1. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting.
    Kariya S; Shimizu Y; Hanai N; Yasumatsu R; Yokota T; Fujii T; Tsukahara K; Yoshida M; Hanyu K; Ueda T; Hirakawa H; Takahashi S; Ono T; Sano D; Yamauchi M; Watanabe A; Omori K; Yamazaki T; Monden N; Kudo N; Arai M; Yonekura S; Asakage T; Fujiwara A; Yamada T; Homma A
    Int J Clin Oncol; 2021 Jun; 26(6):1049-1056. PubMed ID: 33830342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
    Hanai N; Shimizu Y; Kariya S; Yasumatsu R; Yokota T; Fujii T; Tsukahara K; Yoshida M; Hanyu K; Ueda T; Hirakawa H; Takahashi S; Ono T; Sano D; Yamauchi M; Watanabe A; Omori K; Yamazaki T; Monden N; Kudo N; Arai M; Sakurai D; Asakage T; Doi I; Yamada T; Homma A
    Int J Clin Oncol; 2021 Mar; 26(3):494-506. PubMed ID: 33219460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
    Yasumatsu R; Shimizu Y; Hanai N; Kariya S; Yokota T; Fujii T; Tsukahara K; Ando M; Hanyu K; Ueda T; Hirakawa H; Takahashi S; Ono T; Sano D; Yamauchi M; Watanabe A; Omori K; Yamazaki T; Monden N; Kudo N; Arai M; Yonekura S; Asakage T; Nekado T; Yamada T; Homma A
    Int J Clin Oncol; 2022 Jan; 27(1):95-104. PubMed ID: 34773525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
    Ward MC; Shah C; Adelstein DJ; Geiger JL; Miller JA; Koyfman SA; Singer ME
    Oral Oncol; 2017 Nov; 74():49-55. PubMed ID: 29103751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance.
    Tahara M; Kiyota N; Nibu KI; Akamatsu A; Hoshino T; Hayashi R
    Int J Clin Oncol; 2021 Sep; 26(9):1619-1627. PubMed ID: 34110532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
    Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
    Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
    Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
    Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
    Chung CH; Bonomi M; Steuer CE; Li J; Bhateja P; Johnson M; Masannat J; Song F; Hernandez-Prera JC; Wenig BM; Molina H; Farinhas JM; McMullen CP; Wadsworth JT; Patel KB; Kish JA; Muzaffar J; Kirtane K; Rocco JW; Schell MJ; Saba NF
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
    Botticelli A; Mezi S; Pomati G; Sciattella P; Cerbelli B; Roberto M; Mammone G; Cirillo A; Cassano A; Di Dio C; Cortellini A; Pizzuti L; Ronzino G; Salati M; Vici P; Polimeni A; Merlano MC; Nuti M; Marchetti P
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32326034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
    Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
    Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.